The Vanda Board once more evaluated all features of Vanda’s enterprise towards the unsolicited proposals and decided that the proposals are opportunistic makes an attempt to buy the Firm’s shares at a reduction to Vanda’s intrinsic worth. The Board’s prior analysis of the corporate’s scientific growth pipeline, increasing industrial presence and important money steadiness stays unchanged. The Board additionally reached the identical conclusion because it reached beforehand concerning the speculative nature of the CVRs given the uncertainty surrounding the achievement of the industrial milestones below FP’s administration.
The Board and administration crew stay assured that Vanda’s sturdy income, sturdy money place and environment friendly operations place the Firm nicely for important long-term progress and worth creation far in extra of the consideration provided by Cycle Group and FP.
There isn’t any motion for shareholders to take presently.
About Vanda Prescription drugs Inc.
Vanda is a number one international biopharmaceutical firm centered on the event and commercialization of modern therapies to handle excessive unmet medical wants and enhance the lives of sufferers. For extra on Vanda Prescription drugs Inc., please go to www.vandapharma.com and observe us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Numerous statements on this press release, together with, however not restricted to, statements concerning the Board’s evaluation of the Cycle Group and FP proposals and the arrogance that the Board and administration crew have within the Firm’s long-term prospects for progress and worth creation, are “forward-looking statements” below the securities legal guidelines. All statements apart from statements of historic reality are statements that could possibly be deemed forward-looking statements. Ahead-looking statements are based mostly upon present expectations and assumptions that contain dangers, adjustments in circumstances and uncertainties. Subsequently, no assurance will be on condition that the outcomes or developments anticipated by Vanda will likely be realized or, even when considerably realized, that they are going to have the anticipated penalties to, or results on, Vanda. Ahead-looking statements on this press release ought to be evaluated along with the varied dangers and uncertainties that have an effect on Vanda’s enterprise and market, notably these recognized within the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most up-to-date Annual Report on Kind 10-Okay, as up to date by Vanda’s subsequent Quarterly Experiences on Kind 10-Q, Present Experiences on Kind 8-Okay and different filings with the U.S. Securities and Trade Fee, which can be found at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any individual appearing on its behalf are expressly certified of their entirety by the cautionary statements contained or referred to herein. Vanda cautions buyers to not rely too closely on the forward-looking statements Vanda makes or which can be made on its behalf. The data on this press release is offered solely as of the date of this press release, and Vanda undertakes no obligation, and particularly declines any obligation, to replace or revise publicly any forward-looking statements, whether or not because of new data, future occasions or in any other case, besides as required by regulation.
Company Contact:
Vanda Prescription drugs Inc.
202-734-3400
pr@vandapharma.com
VANDA-CS@collectedstrategies.com